94. Primary sclerosing cholangitis Clinical trials / Disease details
Clinical trials : 148 / Drugs : 118 - (DrugBank : 39) / Drug target genes : 18 - Drug target pathways : 141
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-UMIN000021411 | 2016/04/01 | 01/04/2016 | clinical efficacy of oral administration of metronidazole in the treatment of primary sclerosing cholangitis | clinical efficacy of oral administration of metronidazole in the treatment of primary sclerosing cholangitis - clinical efficacy of oral administration of metronidazole in the treatment of PSC | primary sclerosing cholangitis | Patients take metronidazole 250mg orally three times day for 3 weeks. | Keio University, School of Medicine | NULL | Complete: follow-up complete | 16years-old | Not applicable | Male and Female | 20 | Not applicable | Japan |
| 2 | NCT01085760 (ClinicalTrials.gov) | February 2010 | 10/3/2010 | A Pilot Study of Vancomycin or Metronidazole in Patients With Primary Sclerosing Cholangitis | A Pilot Study of Vancomycin or Metronidazole in Patients With Primary Sclerosing Cholangitis | Primary Sclerosing Cholangitis | Drug: Vancomycin;Drug: Metronidazole | Mayo Clinic | PSC Partners Seeking a Cure Foundation | Completed | 18 Years | 75 Years | All | 35 | Phase 1 | United States |